Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor

Cancer Letters

Volumn 148, Issue 1, 2000, Pages 33-37

  Kawamori, Toshihiko ^a   Takahashi, Mami ^a   Watanabe, Kouji ^a   Ohta, Toshihisa ^a   Nakatsugi, Seiichi ^a   Sugimura, Takashi ^a   Wakabayashi, Keiji ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Aberrant crypt foci; Azoxymethane; Chemoprevention; Colon; Nitric oxide synthase inhibitor

Indexed keywords

AZOXYMETHANE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CELL PROLIFERATION; CHROMOSOME NOR; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; INTESTINE CRYPT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SILVER STAINING;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIGENS, NUCLEAR; AZOXYMETHANE; BODY WEIGHT; CARCINOGENS; CELL DIVISION; CELL NUCLEUS; COLON; COLONIC NEOPLASMS; INTESTINAL MUCOSA; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NUCLEAR PROTEINS; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344;

ANIMALIA; RODENTIA;

EID: 0033988477     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00310-9     Document Type: Article

References (28)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J. Clin. 48:1998;6-29.
2. Tajima K., Hirose K., Nakagawa N., Kuroishi T., Tominaga S. Urban-rural difference in the trend of colorectal cancer mortality with special reference to the subsites of colon cancer in Japan. Jpn. J. Cancer Res. 76:1985;717-728.
3. Nathan C., Xie Q.W. Nitric oxide synthases: roles, tolls, and controls. Cell. 78:1994;915-918.
4. Schmidt H.H., Walter U. at work. Cell. 78:1994;919-925.
5. Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 54:1994;1352-1354.
6. Thomsen L.L., Miles D.W., Happerfield L., Bobrow L.G., Knowles R.G., Moncada S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer. 72:1995;41-44.
7. Cobbs C.S., Brenman J.E., Aldape K.D., Bredt D.S., Israel M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55:1995;727-730.
8. Ambs S., Merriam W.G., Bennett W.P., Felley-Bosco E., Ogunfusika M.O., Oser S.M., Klein S., Shields P.G., Billiar T.R., Harris C.C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58:1998;334-341.
9. Chhatwal V.J., Ngoi S.S., Chan S.T., Chia Y.W., Moochhala S.M. Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding peritumoral normal mucosa. Carcinogenesis. 15:1994;2081-2085.
10. Moochhala S., Chhatwal V.J., Chan S.T., Ngoi S.S., Chia Y.W., Rauff A. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis. 17:1996;1171-1174.
11. Takahashi M., Fukuda K., Ohata T., Sugimura T., Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res. 57:1997;1233-1237.
12. Wink D.A., Kasprzak K.S., Maragos C.M., Elespuru R.K., Misra M., Dunams T.M., Cebula T.A., Koch W.H., Andrews A.W., Allen J.S., et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 254:1991;1001-1003.
13. Gal A., Wogan G.N. Mutagenesis associated with nitric oxide production in transgenic SJL mice. Proc. Natl. Acad. Sci. USA. 93:1996;15102-15107.
14. Andrade S.P., Hart I.R., Piper P.J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br. J. Pharmacol. 107:1992;1092-1095.
15. Maeda H., Noguchi Y., Sato K., Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85:1994;331-334.
16. Dwyer M.A., Bredt D.S., Snyder S.H. Nitric oxide synthase: irreversible inhibition by L-NG-nitroarginine in brain in vitro and in vivo. Biochem. Biophys. Res. Commun. 176:1991;1136-1141.
17. Kawamori T., Tanaka T., Hara A., Yamahara J., Mori H. Modifying effects of naturally occurring products on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Cancer Res. 55:1995;1277-1282.
18. Bird R.P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 37:1987;147-151.
19. McLellan E.A., Bird R.P. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res. 48:1988;6187-6192.
20. Pretlow T.P., Barrow B.J., Ashton W.S., O'Riordan M.A., Pretlow T.G., Jurcisek J.A., Stellato T.A. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res. 51:1991;1564-1567.
21. Kawamori T., Tanaka T., Ohnishi M., Hirose Y., Nakamura Y., Satoh K., Hara A., Mori H. Chemoprevention of azoxymethane-induced colon carcinogenesis by dietary feeding of S-methyl methane thiosulfonate in male F344 rats. Cancer Res. 55:1995;4053-4058.
22. Zhang X.M., Stamp D., Minkin S., Medline A., Corpet D.E., Bruce W.R., Archer M.C. Promotion of aberrant crypt foci and cancer in rat colon by thermolyzed protein. J. Natl. Cancer Inst. 84:1992;1026-1030.
23. Pretlow T.P., O'Riordan M.A., Somich G.A., Amini S.B., Pretlow T.G. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis. 13:1992;1509-1512.
24. Rao C.V., Kawamori T., Hamid R., Reddy B.S. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis. 20:1999;641-644.
25. Salvemini D., Settle S.L., Masferrer J.L., Seibert K., Currie M.G., Needleman P. Regulation of prostaglandin production by nitric oxide: an in vivo analysis. Br. J. Pharmacol. 114:1995;1171-1178.
26. Wu J., Akaike T., Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58:1998;159-165.
27. Fakan S., Hernandez-Verdun D. The nucleolus and the nucleolar organizer regions. Biol. Cell. 56:1986;189-205.
28. Tanaka T., Takeuchi T., Nishikawa A., Takami T., Mori H. Nucleolar organizer regions in hepatocarcinogenesis induced by N-2-fluorenylacetamide in rats: comparison with bromodeoxyuridine immunohistochemistry. Jpn. J. Cancer Res. 80:1989;1047-1051.